News

US FDA pauses Gilead trials testing experimental HIV pill combination
The U.S. Food and Drug Administration has paused Gilead Sciences' trials testing a combination of two of its experimental HIV ...
US FDA places clinical hold on Gilead trials testing HIV pill combination
The U.S. Food and Drug Administration has placed a clinical hold on Gilead Sciences' trials testing a combination of two of ...
BioSpace9h
Gilead’s HIV Combo on Hold, With No Impact on FDA’s Pending Lenacapavir Decision
Gilead underscored its faith in the combo therapy and pledged to work with regulators to resolve the hold, which has paused ...
Fierce Biotech9h
FDA slaps clinical hold on multiple Gilead HIV combo therapy trials, shares fall
Gilead has been hit with a clinical hold from the FDA for five tests of its experimental HIV combination treatment amid ...
Why Gilead Scinces Stock Tumbled on Tuesday
The U.S. FDA ordered a pause on clinical trials of a combination therapy for HIV. This won't affect the company's other HIV ...
Gilead commits to HIV prevention rollout for low-income countries despite funding uncertainty
Walmart's Flipkart has secured a lending licence from the Indian central bank and banking regulator, enabling it to offer ...
A New Shot Prevents HIV—and Breathes New Life Into a Stagnant Biotech
After years of stagnation, Gilead is betting that a twice-yearly HIV shot can restart its growth engine.
Gilead's HIV Pipeline Gains Traction With Upcoming FDA Decision For HIV-1 Drug
Gilead's HIV drug lenacapavir earns FDA priority review after strong trial results, with the company planning to double U.S.
Gilead Sciences, Inc. (GILD) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
Gilead Sciences, Inc. ( NASDAQ: GILD) Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 11:20 AM ET Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division ...
Gilead Sciences shares hit after HIV studies placed on hold by FDA
Shares of Gilead Sciences (NASDAQ: NASDAQ:GILD) declined 4% on Tuesday after the company announced that the FDA placed clinical holds on studies of several of its HIV drugs.
Long-lasting HIV prevention shot heads toward approval
A new injection to prevent HIV is expected to be approved by the U.S. Food and Drug Administration later this month.
US FDA places clinical hold on 2 Gilead trials of weekly HIV pill combination
The U.S. Food and Drug Administration has placed a clinical hold on Gilead Sciences' trials testing a combination of two of ...